https://www.chamfondbiotech.com/4-types-of-bone-marrow-biopsy-needles/

In the field of diagnosis and treatment of hematological diseases, the bone marrow biopsy needle is an indispensable "key" in the hands of doctors. What it obtains is not just a few milliliters of bone marrow fluid or a small piece of tissue, but rather the gold standard for unlocking the essence of the disease and decoding life information. Especially in the diagnosis and classification of malignant hematological diseases such as leukemia, lymphoma, and myelodysplastic syndrome (MDS), its role is irreplaceable.

For acute leukemia, the role of bone marrow biopsy needles lies in the "qualitative" and "quantitative" aspects. The bone marrow fluid obtained through aspiration can be examined through cell morphology to observe whether the proportion of primitive cells exceeds the diagnostic threshold of 20%. At the same time, flow cytometry and cytogenetic analysis also rely on this valuable liquid sample to identify abnormal immune phenotypes and chromosome karyotypes, thereby accurately determining the subtype of leukemia (such as M0-M7). The core biopsy can provide more critical "spatial information": it can reveal the composition of bone marrow cells, assess the degree of proliferation of hematopoietic tissue (whether it is extremely active or low), and detect whether there are fibrotic or necrotic areas. This is crucial for differentiating acute leukemia from aplastic anemia or determining whether a true complete remission has been achieved after treatment.

In the diagnosis and treatment of lymphoma, the bone marrow biopsy needle is the core tool for staging diagnosis. Many types of lymphoma (especially indolent lymphoma) are highly prone to invading the bone marrow. A positive bone marrow biopsy result indicates that the disease has reached stage IV (advanced stage), which will directly affect the choice of treatment plan - from local radiotherapy to systemic chemotherapy, or the use of targeted drugs. The advantage of core biopsy is prominently demonstrated here: it can completely extract the tissues infiltrated by lymphoma cells, allowing pathologists to clearly observe the destructive growth pattern of lymphocytes and confirm their source (B cells or T cells) through immunohistochemical staining, which is difficult to achieve solely through aspiration smears.

For complex clonal hematopoietic stem cell diseases like MDS, the value of the bone marrow biopsy needle lies in its "panoramic" assessment capability. The diagnosis of MDS relies on the abnormal development of one or more blood cell lineages in the bone marrow (pathological hematopoiesis) and the proportion of primitive cells. The aspirated sample can well demonstrate the heterogeneity of cell morphology, but often underestimates fibrosis or low proliferation due to uneven cell distribution. At this time, the core biopsy sample becomes particularly important, as it can clearly show the "architecture" of the bone marrow - the size of the hematopoietic islands, the distribution of fat cells, and whether there are abnormal immature precursor cells aggregating (the ALIP phenomenon), all of which are key bases for the diagnosis and prognosis judgment of MDS. It can be said that without the bone marrow biopsy needle, there would be no precise diagnosis in modern hematological oncology.